Related by context. All words. (Click for frequent words.) 74 oral prodrug 74 sodium glucose cotransporter 74 investigational humanized monoclonal antibody 73 vidofludimus 72 Mipomersen 72 PDE4 inhibitor 72 selective androgen receptor modulator 72 virus HCV protease inhibitor 72 nucleoside analog 72 AEG# 71 Cloretazine ® 71 fosbretabulin 71 metaglidasen 71 Blinatumomab 71 orally dosed 71 TBC# 71 HGS# 71 OXi# 71 TLK# 71 PRT# 71 Triolex 71 orally administered inhibitor 70 PS# [001] 70 INCB# [001] 70 liposomal formulation 70 vascular disrupting agent 70 JAK inhibitor 70 phase IIb clinical 70 MEK inhibitor 70 elotuzumab 70 Aflibercept 70 anticancer compound 70 Dapagliflozin 70 otelixizumab 70 Carfilzomib 70 BAY #-# 70 PEG SN# 70 IMC A# 70 HGS ETR2 70 selective modulator 70 AEGR 70 highly selective inhibitor 70 R#/MEM # 70 CCX# 70 ISIS # 69 pertuzumab 69 PSN# [001] 69 Phase Ib clinical 69 preclinical efficacy 69 cannabinor 69 Symadex 69 AKT inhibitor 69 TELINTRA 69 mapatumumab 69 ZK EPO 69 angiogenesis inhibitor 69 JAK2 inhibitor 69 LY# [003] 69 evaluating tivozanib 69 Zybrestat 69 Sapacitabine 69 receptor tyrosine kinase inhibitor 69 davalintide 69 Guanilib 69 Panzem R 69 NOX E# 69 teduglutide 69 ganetespib 69 Nanobody 69 LY# [002] 69 DPP4 inhibitor 69 sorafenib Nexavar 69 Xanafide 69 Factor VIIa 69 Phase Ib study 69 6R BH4 69 CCR9 antagonist 69 Tyrima 69 receptor monoclonal antibody 69 CA4P 69 INS# [001] 69 Sym# 69 insulin sensitizing 69 glucagon receptor 69 favorable pharmacokinetic profile 69 Traficet EN 69 phase IIb trial 69 erlotinib Tarceva ® 69 phase IIa clinical 69 HuLuc# 69 investigational oral 69 polymerase inhibitor 69 Seliciclib 69 Pimavanserin 68 5 HT6 receptor 68 TRO# 68 antidiabetic 68 Phase Ib II 68 ATL# [001] 68 IAP inhibitor 68 EndoTAG TM -1 68 IL# PE#QQR 68 investigational protease inhibitor 68 ENMD # 68 Safinamide 68 intranasal formulation 68 peripherally acting 68 Squalamine 68 Cloretazine 68 Phase IIb trials 68 Archexin 68 RGB # 68 Cannabinor 68 AAG geldanamycin analog 68 mertansine 68 PNP inhibitor 68 trodusquemine 68 entinostat 68 alvespimycin 68 investigational hepatitis C 68 PRX # 68 TKM ApoB 68 ALK inhibitor 68 novel VDA molecule 68 Darusentan 68 orally bioavailable 68 Phase 1b trial 68 CBLC# 68 Apoptone 68 protein kinase inhibitor 68 investigational pan BCR 68 docetaxel Taxotere ® 68 Phase 2b study 68 Dasatinib 68 receptor inhibitor 68 hypoxia activated prodrug 68 Talabostat 68 FOLOTYN ® 68 Posiphen 68 non nucleoside inhibitor 68 HDACi 68 pomalidomide 68 CEQ# 68 signal transduction inhibitor 68 SAR# [002] 68 histone deacetylase inhibitor 68 pharmacodynamic properties 68 Akt inhibitor 68 phase IIb 68 PHX# 68 Perifosine 68 IMC #B 68 tubulin inhibitor 68 lomitapide 68 TH# [003] 68 multicenter Phase II 68 PRTX 68 reslizumab 68 pan HDAC inhibitor 67 VEGF Trap 67 preclinically 67 KRN# 67 Annamycin 67 CaPre TM 67 dexpramipexole 67 anti amnesic 67 Onconase 67 XOMA 3AB 67 EOquin 67 IRX 2 67 SCH # 67 Muraglitazar 67 novel histone deacetylase 67 SERMs 67 CYT# potent vascular disrupting 67 teriflunomide 67 JAK1 67 sunitinib malate 67 glucokinase activator 67 torezolid phosphate 67 docetaxel Taxotere R 67 Bicifadine 67 mGluR5 NAM 67 Androxal TM 67 investigational monoclonal antibody 67 MAGE A3 ASCI 67 diabetic neuropathic pain 67 BZL# 67 ruxolitinib 67 PXD# 67 dose escalation Phase 67 2 methoxyestradiol 67 phase IIb study 67 OMP #M# 67 Kahalalide F 67 ADP receptor antagonist 67 forodesine 67 DXL# 67 epothilone 67 Vitaxin 67 riociguat 67 Cethromycin 67 R roscovitine 67 HGS ETR1 67 albiglutide 67 CYC# 67 Cloretazine R 67 Aplidin 67 MGCD# [001] 67 Hsp# Inhibitor 67 Phase IIb clinical trials 67 Elvitegravir 67 Tasimelteon 67 partial agonist 67 Spiegelmer ® 67 TG# [003] 67 PSMA ADC 67 RhuDex ® 67 Phase #b/#a clinical 67 GLP toxicology studies 67 pramlintide 67 PrevOnco 67 Omacetaxine 67 Phase #b/#a 67 Targretin 67 insulin sensitizers 67 ALN TTR# 67 inhaled formulation 67 mTOR inhibitor 67 HuMax EGFr 67 Zoraxel 67 Epanova 67 Panzem R NCD 67 CB2 selective receptor agonist 67 TRV# [001] 67 proteasome inhibitor 67 ATL/TV# 67 APOPTONE 67 axitinib 67 YONDELIS 67 Bortezomib 67 Saxagliptin 67 DDP# 67 CRx 67 HSP# inhibitor 67 elvitegravir 67 non alcoholic steatohepatitis 67 CDK inhibitor 67 neuroprotective properties 67 Pazopanib 67 sodium thiosulfate STS 67 cMET 67 insulin sensitizer 67 ONCONASE R 67 MEK inhibitors 67 deforolimus 67 corticosteroid dexamethasone 67 Phase 2a trial 67 nalbuphine ER 67 Phase Ib 67 TMC# [002] 67 Aurora Kinase 67 Tesetaxel 67 Lu AA# 67 seliciclib CYC# 67 novel anticancer 67 Ophena TM 67 nucleoside reverse transcriptase inhibitor 67 Trandolapril 66 Vilazodone 66 GW# [003] 66 DCCR 66 selective antagonist 66 MKC# 66 anticancer agent 66 IAP inhibitors 66 PROVENGE sipuleucel T 66 Panzem 66 Tarceva TM 66 Plicera 66 oral nucleoside analogue 66 GSK# [002] 66 Romidepsin 66 Tezampanel 66 huC# DM4 66 HDAC Inhibitor 66 muraglitazar 66 radiation sensitizer 66 MKC# MKC# PP 66 Exherin TM 66 LEP ETU 66 Initiate Phase 66 neratinib 66 tezampanel 66 Elagolix 66 Chemophase 66 HCV NS5B polymerase 66 DU #b 66 ATL# [002] 66 Tarvacin TM 66 solithromycin 66 davunetide intranasal AL 66 Phase 2b Clinical Trial 66 PDX pralatrexate 66 visilizumab 66 antibody MAb 66 glucose lowering 66 muscarinic 66 anti fibrotic 66 talabostat 66 cytoprotective 66 Ostarine 66 preclinical pharmacokinetic 66 IND submission 66 vascular disrupting agents 66 small molecule tyrosine 66 compound INCB# 66 non nucleoside HCV 66 TRX1 66 tipifarnib 66 kinase inhibitor 66 PEG Interferon lambda 66 Randomized Phase 66 Vicriviroc 66 CCR5 antagonist 66 retapamulin 66 #D#C# 66 targeting CD# 66 cetuximab Erbitux R 66 PD LID 66 ARRY # 66 Trofex 66 tanespimycin 66 JZP 66 brivaracetam 66 nonclinical studies 66 ALN TTR 66 cathepsin K inhibitor 66 MEK inhibitor RDEA# 66 Lisofylline LSF 66 nucleotide analog 66 generation antisense inhibitor 66 Amrubicin 66 XL# XL# 66 GPR# agonist 66 aurora kinase 66 alagebrium 66 Menerba 66 Angiolix 66 Laquinimod 66 Phase 2b clinical trials 66 generation purine nucleoside 66 Aurora kinase inhibitor 66 TRIOLEX 66 Azedra 66 varespladib 66 Phase IIa trial 66 SAR# [004] 66 receptor antagonists 66 selective inhibitor 66 midstage clinical 66 oral antidiabetic 66 rhIGFBP 3 66 ARIKACE ™ 66 tramiprosate Alzhemed TM 66 integrase inhibitor 66 trastuzumab Herceptin R 66 PANVAC VF 66 thalidomide Thalomid 66 AQ4N 66 RNAi therapeutic targeting PCSK9 66 budesonide foam 66 IMA# 66 INCB# [003] 66 HuMax CD# 66 phase IIa 66 PI3K/Akt pathway inhibitor 66 MLN# 66 Silodosin 66 PEG IFN 66 Meets Primary Endpoint 66 receptor modulators 66 mecamylamine 66 pharmacokinetic PK study 66 Asentar 66 chemopreventive agent 66 ulimorelin 66 Phase #b/#a trial 66 Atiprimod 66 imatinib Gleevec ® 66 CYT# 66 Alocrest 66 GLYX 66 Phase IIa trials 66 Telintra 66 IMiDs R 66 DPP4 66 eniluracil 66 rALLy 66 HCV protease 66 eprotirome 66 Microplasmin 66 Fx #A 66 VNP#M 66 selective kinase inhibitor 66 mGluR2 NAM 66 Pertuzumab 66 Glufosfamide 66 TKB# 66 CR# vcMMAE 66 Kamada AAT 66 CG# [003] 66 QNEXA 66 including eniluracil ADH 66 Phase 1a clinical 66 midstage trials 66 Angiocept 66 preclinical studies 66 anti secretory 66 Degarelix 66 CLORETAZINE TM VNP#M 66 Enzastaurin 65 depsipeptide 65 pharmacokinetic PK profile 65 MKC# MT 65 SARMs 65 YONDELIS R 65 SUTENT ® 65 PS# DARA 65 Granulocyte Colony Stimulating Factor 65 ApoB SNALP 65 CCR9 65 anti angiogenic agent 65 pramlintide metreleptin 65 anti CD3 65 Aplidin R 65 nitazoxanide 65 Deforolimus 65 HQK 65 renin inhibitors 65 multi kinase inhibitor 65 velafermin 65 valopicitabine 65 Zolinza 65 prucalopride 65 inhibitor RG# 65 AOD# [002] 65 BMS# 65 dipeptidyl peptidase IV 65 5 HT2A inverse 65 Initiated Phase 65 Proellex TM 65 AVE# 65 Virulizin ® 65 huN# DM1 65 LAF# 65 lumiliximab 65 HCV protease inhibitors 65 PDE# inhibitors 65 RhuDex 65 Phase 2a clinical 65 RNAi therapeutic targeting 65 romazarit 65 CRLX# 65 phase Ib 65 selective agonist 65 BMS # 65 PEGylated 65 Lubiprostone 65 alkylating agent 65 Aurora kinase 65 histamine dihydrochloride 65 endothelin receptor 65 Tolvaptan 65 incyclinide 65 ORMD 65 octreotide implant 65 gefitinib Iressa 65 Ceflatonin 65 AZILECT R 65 AP# [003] 65 SILENOR 65 Androxal ® 65 Sphingomab 65 Naproxcinod 65 thetreatment 65 small molecule Hedgehog 65 angiotensin receptor blocker ARB 65 anti leukemic 65 novel peptide 65 OvaRex ® MAb 65 posaconazole 65 Kinase Inhibitor 65 Oral NKTR 65 protein tyrosine phosphatase 1B 65 Empatic 65 investigational compound 65 Bezielle 65 Radezolid 65 sorafenib tablets 65 tumor necrosis 65 CORT # 65 Genasense ® oblimersen 65 mitogen activated ERK kinase 65 antidiabetic drug 65 Vidaza azacitidine 65 dasatinib Sprycel ® 65 p# inhibitor 65 HCV protease inhibitor 65 diarrhea predominant irritable 65 MORAb 65 lexidronam injection 65 celgosivir 65 mTOR inhibitors 65 Phase IIB 65 Ridaforolimus 65 Cetrorelix 65 GLPG# 65 castrate resistant prostate cancer 65 bicifadine 65 Elotuzumab 65 dosing cohort 65 histone deacetylase HDAC inhibitor 65 Phase 2a Clinical Trial 65 atacicept 65 Phase Ib clinical trials 65 SGLT2 65 Onalta ™ 65 oral JAK1 65 Golimumab 65 MGCD# [002] 65 systemically administered 65 CINTREDEKIN BESUDOTOX 65 CIMZIA ™ 65 AzaSite Plus 65 LHRH antagonists 65 tiapamil 65 Iloperidone 65 sitaxsentan 65 CD# monoclonal antibody 65 MDV# 65 Aliskiren 65 SinuNase ™ 65 Ticagrelor 65 Candesartan 65 Zorbtive TM 65 Pivotal Phase III 65 PROSTASCINT R 65 #ME# 65 MAP# 65 mGluR5 negative 65 telomerase therapeutic 65 Phase III Clinical Trials 65 Cloretazine R VNP#M 65 ALN HPN 65 Elesclomol 65 pharmacodynamic profile 65 omega interferon 65 oral anticancer 65 Atrasentan 65 Tanespimycin 65 antitumor effects 65 Vidofludimus 65 CIMZIA TM 65 ISTODAX 65 Presents Preclinical 65 itraconazole Sporanox 65 Lixivaptan 65 PF # [001] 65 trial evaluating PRX# 65 cardioprotective effects 65 Presents Preclinical Data 65 Pivotal Phase 65 enzastaurin 65 orally administered 65 cetuximab Erbitux 65 selective inhibition 65 Nasulin 65 rBChE 65 Hsp# inhibitor 65 delafloxacin 65 nab paclitaxel 65 nucleoside analogues 65 small molecule thrombopoietin 65 VAPRISOL 65 dacetuzumab 65 tasimelteon 65 TAFA# 65 Phase 1b 65 Thiovir 65 Phase III Clinical Trial 65 Panzem NCD 65 HGS ETR1 mapatumumab 65 eltrombopag 65 BRAF inhibitor 65 obatoclax 65 targeted radiotherapeutic 65 pharmacokinetics PK 65 Serdaxin ® 65 Troxatyl 65 Phase 2a clinical trials 65 CTAP# Capsules 65 Phase 2b Trial 65 Phenoptin 65 bexarotene 65 ZOLINZA 65 rNAPc2 65 Trodusquemine MSI 65 Maribavir 64 leading oral taxane 64 RhuDex TM 64 Quinamed 64 APD# 64 Denufosol 64 IGF 1R inhibitor 64 Ophena 64 5 HT2C serotonin 64 TLR9 agonist 64 Telmisartan 64 GRNCM1 64 Valsartan 64 DOS# 64 highly selective endothelin 64 Telbivudine 64 SGLT2 inhibitor 64 maximally tolerated dose 64 Febuxostat 64 severe gastroparesis 64 receptor agonist 64 dihydrochloride 64 preclinical 64 GALNS 64 PYY #-# 64 Calcitonin 64 Phase 2a 64 EOquin TM 64 candidate CRLX# 64 topically administered 64 Orally administered 64 AVN# [001] 64 oral antiviral 64 KNS # 64 Avanafil 64 Preclinical studies suggest 64 XL# XL# XL# 64 Aurexis 64 XmAb# 64 torezolid 64 class mGluR5 inhibitor 64 administered subcutaneously 64 ongoing Phase 1b 64 JAK inhibitors 64 lapatinib Tykerb 64 Varespladib 64 Eltrombopag 64 Myocet 64 double blinded placebo 64 selective androgen receptor modulators 64 erlotinib Tarceva 64 Initiates Enrollment 64 Personalized Immunotherapy 64 OHR/AVR# 64 Serdaxin 64 Phase 2b 64 Phase IIb Trial 64 FBPase 64 liprotamase 64 FOLFOX6 chemotherapy regimen 64 pharmacokinetic studies 64 Linaclotide 64 NV1FGF 64 registrational 64 metastatic castration resistant 64 QLT# 64 Initiates Clinical 64 EGS# 64 Initiates Phase III 64 Protelos 64 radezolid 64 panitumumab Vectibix 64 Sphingosine 1 64 KSP inhibitor 64 torsemide ER 64 thymalfasin 64 PKC# 64 Civacir 64 Shigamabs ® 64 MGd 64 Hedgehog Pathway Inhibitor 64 SRT# [003] 64 GED aPC 64 APTIVUS 64 CCR2 64 CD# CEA 64 EP #R 64 potent inhibitor 64 Ceflatonin R 64 AMD# [003] 64 Cloretazine VNP#M 64 HDL Mimetic Peptide 64 BNC# 64 Phase IIIb clinical 64 BRIM3 64 metformin sulfonylurea 64 VA# [002] 64 adecatumumab 64 Ozarelix 64 Pegloticase 64 PI3K/mTOR 64 Eniluracil 64 ADVANCE PD 64 immune modulating 64 pharmacodynamic effects 64 AERx iDMS 64 RhuDex R 64 urocortin 2 64 ancrod 64 VEGF inhibitors 64 THR beta agonist 64 perampanel 64 Liraglutide 64 talactoferrin 64 OvaRex R 64 oral dihydropyrimidine dehydrogenase DPD 64 immunomodulatory 64 anti EGFR antibody 64 Parathyroid Hormone 64 selectively inhibit 64 TOCOSOL Paclitaxel 64 TriRima 64 JAK Inhibitor 64 TACI Ig 64 trastuzumab DM1 T DM1 64 HCV polymerase 64 direct thrombin inhibitors 64 iniparib 64 GFT# 64 antithrombotic 64 NXL# 64 Zoraxel TM 64 demonstrated antitumor activity 64 generation antisense 64 hyperlipidemic 64 Triapine R 64 delta opioid receptor 64 ILUVIEN ® 64 beta 1a 64 tesofensine 64 epigenetic therapies 64 MAb 64 Anidulafungin 64 tafamidis 64 small molecule agonists 64 DAVANAT 64 PROSTVAC TM 64 desvenlafaxine succinate 64 Synavive 64 apremilast 64 nucleoside 64 Nuvion 64 Proxinium TM 64 BN# [002] 64 regorafenib 64 CDP# 64 rALLy clinical trial 64 NS#/#A protease 64 lucinactant 64 Anti Tumor 64 generation Hsp# inhibitor 64 JAK2 Inhibitor 64 HIV integrase inhibitor 64 CoFactor 64 iSONEP 64 HepeX B TM 64 Dyloject TM 64 Tofacitinib 64 PEG PAL 64 Fibrillex TM 64 R lenalidomide 64 adecatumumab MT# 64 PPARγ 64 Octreotide 64 LT NS# 64 BRIM2 64 IMiDs ® 64 trastuzumab DM1 64 alefacept 64 Phase 1b clinical trials 64 olaparib 64 somatostatin analogue 64 compound AEZS 64 IDX# 64 Alfimeprase 64 Afatinib 64 ocular formulation 64 gamma secretase inhibitor 64 vinca alkaloid 64 Phase IIa 64 Capesaris 64 volociximab 64 GRN#L 64 ALS #-# 64 XL# anticancer compounds 64 LymphoStat B TM 64 Phase Ia 64 receptor partial agonist 64 DermaVir Patch 64 Hsp# inhibitors 64 lenalidomide Revlimid R 64 investigational compounds 64 epothilones 64 Epratuzumab 64 Tavocept 64 reversible inhibitor 64 Alzhemed TM 64 novel prodrug 64 Solulin 64 Glucagon Like Peptide 64 HDAC inhibitor 64 Pagoclone 64 casopitant 64 INT# [002] 64 vismodegib 64 VitiGam 64 Ocrelizumab 64 Abiraterone acetate 64 Voreloxin 64 EndoTAG 64 tocilizumab 64 Liposomal 64 VEGF receptor 64 Preclinical studies 64 oral salmon calcitonin 64 ELND-#/AZD-# 64 Amplimexon 64 Randomized Double blind 64 NN# [001] 64 Valdoxan 64 Xcytrin R 64 zanolimumab 64 5 HT3 antagonist 64 ANCHOR trial 64 uric acid lowering 64 Pathway Inhibitor 64 antisense drug 64 anticancer activity 64 pegylated liposomal doxorubicin 64 Phase III Pivotal 64 acetonide FA 64 TELCYTA 64 ospemifene 64 humanized monoclonal 64 BCR ABL inhibitor 64 Nexavar sorafenib 64 BAL# [002] 64 HDAC inhibition 64 ICA # 64 canakinumab 64 dasatinib Sprycel 64 alpha#beta# integrin 64 ixabepilone 64 ritonavir boosted 64 GEM OS2 64 Inhalation Solution 64 Ambrisentan 64 isoform selective 64 urate lowering 64 Alogliptin 64 CCR5 mAb 64 pradefovir 64 Marqibo 64 Interferon alpha 64 potent anticancer 64 Sitagliptin 64 PREOS R 64 TOCOSOL Camptothecin 64 Initiates Phase 2b 64 SNT MC# 64 RELOVAIR ™ 63 Fenretinide 63 bevacizumab Avastin ® 63 gemcitabine Gemzar 63 hypoxia inducible factor 63 Ostabolin C 63 potent antiproliferative 63 Pafuramidine 63 HCV SPRINT 63 teplizumab 63 vaccine GRNVAC1 63 Prodarsan ® 63 Rebif ® 63 anti angiogenic agents 63 relapsed MCL 63 ALN PCS 63 dipeptidyl peptidase 4 63 SELZENTRY 63 Methylnaltrexone 63 Sudhir Agrawal D.Phil 63 ularitide 63 lintuzumab SGN 63 cilengitide 63 gastrin 63 placebo controlled Phase 63 TRIOLEX ™ 63 proteasome inhibitors 63 chemokine receptor 63 olmesartan 63 MAXY alpha 63 neuroprotectant 63 E2F Decoy 63 resolvin 63 Vernakalant 63 Corlux 63 DGAT 63 oral rivaroxaban 63 ganaxolone 63 Initiates Phase II 63 multitargeted 63 sphingosine 1 63 Darapladib 63 VEGFR2 inhibitor 63 IL #E 63 cyclophilin inhibitor 63 humanized monoclonal antibody 63 iroxanadine 63 phase IIIb 63 Onrigin 63 candesartan cilexetil 63 oral ghrelin agonist 63 vemurafenib 63 cariprazine 63 TNFα 63 Reverset 63 telaprevir VX 63 Phase IIb 63 dextromethorphan quinidine 63 NEUGENE 63 Panitumumab 63 Elocalcitol 63 LymphoStat B belimumab 63 dextofisopam 63 cobiprostone 63 Phase IIa clinical trials 63 SPC# [001] 63 vosaroxin 63 Phase 2b trial 63 antisense inhibitors 63 SB# ONX 63 GRN# 63 xanthine oxidase inhibitor 63 non nucleoside 63 MTP inhibitor 63 LUVENIQ 63 Resten NG 63 drug GLPG# 63 abiraterone acetate 63 DB# [003] 63 inhibit metastasis 63 PROSTVAC VF 63 Exelixis compounds 63 Cyclooxygenase Inhibiting Nitric Oxide 63 TNFa 63 cancer immunotherapies 63 Luteinizing Hormone Releasing Hormone 63 CD# antibody [001] 63 ESBA# 63 mTOR inhibition 63 VIAject 63 VEGF inhibitor 63 xenograft models 63 Solazed TM 63 plasma kallikrein 63 clevidipine 63 Pramlintide 63 ELND# 63 PGL# 63 baminercept 63 systemic RNAi therapeutic 63 DFMO 63 viral kinetics 63 Phase 2a Study 63 rxRNA 63 ON #.Na 63 selective adenosine 63 TÎ ² 4 63 fostamatinib 63 Vandetanib 63 Receptor Agonist 63 oral FTY# 63 Linagliptin 63 ZYBRESTAT fosbretabulin 63 RezularTM 63 GATTEX ™ 63 gemcitabine Gemzar ® 63 PPAR gamma agonist 63 tyrosine kinase inhibitor 63 therapeutic monoclonal antibody 63 etanercept Enbrel 63 Zenvia ™